Monoclonal antibody prevents malariainfection in African adults NIAIDNews nejm
An antibody drug called CIS43LS prevents malaria infection by interrupting the lifecycle of the Plasmodium falciparum parasite. The antibody binds to and neutralizes sporozoites, the stage of the parasite transmitted from mosquitos to humans. Credit: NIH
An estimated 241 million cases of malaria occurred worldwide in 2020, according to the World Health Organization , resulting in an estimated 627,000 deaths, mostly in children in sub-Saharan Africa. These cases included more than 11 million pregnant women in Africa, resulting in an estimated 819,000 newborns with low birthweight and thus at increased risk for illness and death.
The Phase 2 NIAID-USTTB trial evaluated the safety and efficacy of a one-time, intravenous infusion of a monoclonal antibody called CIS43LS. This antibody was previously shown to neutralize the sporozoites of P. falciparum in the skin and blood before they could infect liver cells. Researchers led by Robert A. Seder, M.D.
The second part of the trial assessed the efficacy of two different doses of CIS43LS compared to a placebo. Three hundred and thirty participants were assigned at random to receive either 10 mg/kg of the antibody, 40 mg/kg, or a placebo by intravenous infusion. No one knew who was assigned to which group until the end of the trial. The study team followed these individuals for 24 weeks, testing their blood for P. falciparum weekly for the first 28 days and every two weeks thereafter.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
New research suggests booster dose of Novovax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariantsA new study evaluated the neutralizing antibody titers against the SARS-CoV-2 Omicron variant and its sub-lineages after two and three doses of the Novovax protein nanoparticle vaccine NVX-CoV2373.
Læs mere »
Hopes grow for 'Covid-free Christmas' with infections fallingBrits are likely to enjoy a relatively Covid-free Christmas for the first time in three years, experts have predicted 🎅😷
Læs mere »
Italian study evaluates COVID-19 reinfection risk among previously infected and vaccinated individualsItalian study evaluates COVID-19 reinfection risk among previously infected and vaccinated individuals UniAvogadro researchsquare COVID19 SARSCoV2 Vaccination Infection
Læs mere »
SARS-CoV-2 Omicron BA.2 less severe than Delta and original OmicronSARS-CoV-2 Omicron BA.2 less severe than Delta and original Omicron Coronavirus Disease COVID Omicron SARSCoV2 JAMANetworkOpen MassGeneralNews Harvard MinervaUni
Læs mere »